Skystar Bio-Pharmaceutical Co SKBI
|
|
|
- Elijah Gaines
- 6 years ago
- Views:
Transcription
1 Morningstar Analyst Rating Page 1 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.01 [ % $ ,594 8, Stock Price PINX:SKBI: % 2017 Morningstar s Take Key Stats Stock Ind Avg Price/Earnings TTM Price/Book 4.3 Price/Sales TTM 4.1 Rev Growth (3 Yr Avg) Net Income Growth (3 Yr Avg) Operating Margin % TTM Net Margin % TTM ROA TTM ROE TTM Debt/Equity 0.6 Financials Fair Value Estimate $ - Consider Buying $ - Consider Selling $ - Fair Value Uncertainty Economic Moat Stewardship Growth C Profitability V Morningstar Credit Rating Relative to Industry - Avg + Annual Quarterly Income Statement Revenue Operating Income Net Income Earnings Per Share Shares Outstanding Dividends Declared Date -- Ex-Dividend Date -- Latest Indicated Dividend Amount Projected Yield % Recent Dividends & Type Amount Splits 11/17/2009 Split 2:1 05/18/2009 Split 1:10 02/16/2006 Split 1:397 11/26/2001 Split 1:15 Competitors Name Price % Chg TTM Sales $ mil Skystar Bio- $ Pharmaceutical Co Johnson & Johnson $ ] 74,361 Roche Holding AG ADR $ [ 53,017 Roche Holding AG Dividend Right Cert. $ ] 53,017 Roche Holding AG $ ] 53,017 Pfizer Inc $ ] 52,471 Recommendations Current Total Analysts: Buy Hold Sell Ownership Fund Owners Insiders Star Rating % Change TTM % Shares Held % Total Assets % Shares Outstanding Weibing Lu 249, R. Scott Cramer Wei Wen Mark D. Chen 23, Bing Mei 7, Balance Sheet Current Assets Non Current Assets Total Assets Current Liabilities Total Liabilities Stockholders' Equity Cash Flow Cash From Operations Capital Expenditures
2 Morningstar Analyst Rating Page 2 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.01 [ % $ ,594 8, Financials Annual Quarterly Free Cash Flow In millions except "EPS". Currency in USD.
3 Page 3 of 6 Industry Classification NAICS Pharmaceutical Preparation Manufacturing (325412) SIC Pharmaceutical and Medicine Industry (3741);Pharmaceutical Preparations (2834) ISIC Manufacture of Pharmaceuticals, Medicinal Chemical and Botanical Products (2100) Operation Details Fiscal Year Ends CIK Year Established Employees (31/12/2013) Full Time Part Time Auditor (31/12/2013) Crowe Horwath (HK) CPA Limited Legal Advisor (06/05/2008) Richardson & Patel LLP Key Executives Weibing Lu/Chairman of the Board and Chief Executive Officer; Wei Wen/Secretary; Bing Mei/Chief Financial Officer Company Profile Skystar Bio-Pharmaceutical Company is a holding company engaged in research, development, manufacturing and distribution of veterinary health care and medical care products in the People's Republic of China. 30-day Avg Volume 0.0Mil Market Cap Net Income 11.0Mil Sales 49.1Mil Sector Healthcare Industry Drug Manufacturers - Major Stock Style 0 Direct Investment No Dividend Reinvestment No
4 Page 4 of 6 Industry Peers Morningstar Rating Market Cap $Mil Net Income $Mil P/S P/B P/E Dividend Yield% 5 Yr Rev CAGR% Med Oper. Margin% Interest Coverage Skystar Bio-Pharmaceutical Co Johnson & Johnson (USD) QQ 370,766 15, Roche Holding AG (USD,CHF) QQQQQ 214,452 9, Roche Holding AG (USD,CHF) 214,452 9, Roche Holding AG (USD,CHF) 214,452 9, Pfizer Inc (USD) QQQ 211,545 9, Novartis AG (USD) QQQ 198,993 6, Novartis AG (USD) 198,993 6, AbbVie Inc (USD) QQQ 151,213 6, Merck & Co Inc (USD) QQQQ 148,073 2, Sanofi SA (USD,EUR) 115,449 9, Sanofi SA (USD,EUR) QQQQ 115,449 9, Bayer AG (USD,EUR) 105,570 7, Bayer AG (USD,EUR) QQQQ 105,570 7, Bristol-Myers Squibb Company (USD) QQQ 100,542 4, Eli Lilly and Co (USD) QQQ 92,524 2, GlaxoSmithKline PLC (USD,GBP) QQQQ 84,410 2, GlaxoSmithKline PLC (USD,GBP) 84,410 2, AstraZeneca PLC (USD) 83,934 3, AstraZeneca PLC (USD) 83,927 3, AstraZeneca PLC (USD) QQ 83,927 3, Chugai Pharmaceutical Co Ltd (USD,JPY) 27,320 67, Chugai Pharmaceutical Co Ltd (USD,JPY) 27,320 67, Astellas Pharma Inc (USD,JPY) 25, , Astellas Pharma Inc (USD,JPY) 25, , Otsuka Holdings Co Ltd (USD,JPY) 23,904 57, Otsuka Holdings Co Ltd (USD,JPY) 23,904 57, Daiichi Sankyo Co Ltd (USD,JPY) 15,804 38, Daiichi Sankyo Co Ltd (USD,JPY) 15,540 38, CSPC Pharmaceutical Group Ltd (USD,HKD) 12,676 2, Ono Pharmaceutical Co Ltd (USD,JPY) 10,533 53, Ono Pharmaceutical Co Ltd (USD,JPY) 10,533 53, Kyowa Hakko Kirin Co Ltd (USD,JPY) 10,129 21, Recordati (USD,EUR) 9, Santen Pharmaceutical Co Ltd (USD,JPY) 6,244 25, Santen Pharmaceutical Co Ltd (USD,JPY) 6,244 25, PT Kalbe Farma Tbk (USD,IDR) 5,748 2,376, PT Kalbe Farma Tbk (USD,IDR) 5,748 2,376, Hutchison China Meditech Ltd (USD) 4, Hutchison China Meditech Ltd (USD) 4, GW Pharmaceuticals PLC (USD,GBP) 2, GW Pharmaceuticals PLC (USD,GBP) 2, Dechra Pharmaceuticals PLC (USD,GBP) 2, Aerie Pharmaceuticals Inc (USD) 2, Cosmo Pharmaceuticals NV (USD,EUR) 2, Haw Par Corp Ltd (USD,SGD) 1, Haw Par Corp Ltd (USD,SGD) 1, Tong Ren Tang Technologies Co Ltd (USD,CNY) 1, Boiron SA (USD,EUR) 1, United Laboratories International Holdings Ltd (USD,CNY) 1, D/E
5 Page 5 of 6 Industry Peers Zogenix Inc (USD) 1, TherapeuticsMD Inc (USD) 1, Virbac SA (USD,EUR) 1, Retrophin Inc (USD) Nichi-Iko Pharmaceutical Co Ltd (USD,JPY) 824 5, Vectura Group PLC (USD,GBP) Torii Pharmaceutical Co Ltd (USD,JPY) 758 3, Vetoquinol SA (USD,EUR) Mayne Pharma Group Ltd (USD,AUD) Tempo Scan Pacific Tbk (USD,IDR) , Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (USD,CNY) Eco Animal Health Group PLC (USD,GBP) AB Science (USD,EUR) Rockwell Medical Inc (USD) Allergy Therapeutics PLC (USD,GBP) Daiken Medical Co Ltd (USD,JPY) 204 1, Opthea Ltd (USD,AUD) SymBio Pharmaceuticals Ltd (USD,JPY) 103-3, ,357.2 Alimera Sciences Inc (USD) PhotoCure ASA (USD,NOK) Oasmia Pharmaceutical AB (USD,SEK) , , Nanoviricides Inc (USD) Pharmaxis Ltd (USD,AUD) Moberg Pharma AB (USD,SEK) Futura Medical PLC (USD,GBP) ,274.6 Tonix Pharmaceuticals Holding Corp (USD) ProPhase Labs Inc (USD) NeuroVive Pharmaceutical AB (USD,SEK) , , Avivagen Inc (USD,CAD) , Sunwin Stevia International Inc (USD) Immune Pharmaceuticals Inc (USD) , Innovus Pharmaceuticals Inc (USD) Alliqua BioMedical Inc (USD) China Pharma Holding Inc (USD) Biostar Pharmaceuticals Inc (USD) Antisense Therapeutics Ltd (USD,AUD) Aoxing Pharmaceutical Co Inc (USD) Integrated Biopharma Inc (USD) Enzyme Bio Systems (USD) ,320.8 Echo Therapeutics Inc (USD) , ,445.6 Nutrastar International Inc (USD) AtheroNova Inc (USD) Nouveau Life Pharmaceuticals Inc (USD) Winston Pharmaceuticals Inc (USD) Hubei Minkang Pharmaceutical Ltd (USD) China Health Resource Inc (USD) Kun Run Biotechnology Inc (USD) Enzymes American Holding Corp Cell Tech International Inc (USD) Biotie Therapies Corp (USD,EUR) Laxai Pharma Ltd (USD) Tongli Pharmaceuticals (USA) Inc (USD) CSPC Pharmaceutical Group Ltd (USD,HKD) 2,
6 Page 6 of 6 Industry Peers Canopus Biopharma Inc JinZangHuang Tibet Pharmaceuticals Inc (USD) GFR Pharmaceuticals Inc (USD) Global Pharmatech Inc (USD) Somatic Systems Inc Emerging World Pharma Inc InterNatural Pharmaceuticals Inc Neurogenesis Inc Pharmaconnect Inc Innovative Holdings Alliance Inc Endocan Corp (USD) Genex Pharmaceutical Inc (USD) Opthea Ltd (USD,AUD) Cipla Ltd (USD,INR) 11, Bohai Pharmaceuticals Group Inc (USD) Star Nutrition Inc Shandong Luoxin Pharmaceutical Group Stock Co Ltd (USD,CNY) ,394.3 Adia Nutrition Inc Merck Tbk (USD,IDR) 157, Shandong Luoxin Pharmaceutical Group Stock Co Ltd (USD,CNY) ,394.3 Beximco Pharmaceuticals Ltd (USD,BDT) 1, Torrent Pharmaceuticals Ltd (USD,INR) 8, Piramal Enterprises Ltd (USD,INR) 14, GlaxoSmithKline Pharmaceuticals Ltd (USD,INR) 3, , Il Yang Pharmaceutical Co Ltd (USD,KRW) 4, Pierrel SpA (USD,EUR) Whanin Pharm Co Ltd (USD,KRW) 22, Shandong Xinhua Pharmaceutical Co Ltd (USD,CNY) Mayne Pharma Group Ltd (USD,AUD) Kyowa Hakko Kirin Co Ltd (USD,JPY) 21, Xi An 38 Fule Health & Advisory Co Ltd Alfresa Holdings Corp (USD,JPY) 31, Dong Xin Bio-Tech Pharmaceutical Inc Dawnrays Pharmaceutical (Holdings) Ltd (USD,CNY) ,123.9 Artec Inc NV Global Green Inc (USD) Industry Average 36,468 52, , ,
Skystar Bio-Pharmaceutical Co SKBI
Morningstar Analyst Rating Page 1 of 6 Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 0.00 [0.00 0.00 % $ 0.00 0.00-0.00 0.00-0.10
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 6 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 86.57 ]1.05 1.23 % $ 86.09 85.93-86.75
Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF
Page 1 of 7 Morningstar Analyst Rating. Last Price Day Change Open Price Day Range 52-Week Range Proj. Yield Market Cap Volume Avg Vol. Forward P/E P/B P/S P/CF $ 108.67 [-0.90-0.82 % $ 109.49 108.45-109.68
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the
(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K
DCRI Commercial relationships Tracking Form Year: 2018 Name: Adrian Hernandez, M.D. Title: Vice Dean, Clinical, School of Medicine Address: 200 Trent Dr., Durham NC 27710 Please complete the applicable
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the calendar
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION) Feedback from 93 Eastern-European patient groups PUBLISHED JULY 2016 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID
GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS
GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS PHM006K March 2016 Himani Singhi Wadhwa Project Analyst ISBN: 1-62296-254-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
Method of Declaration. Hospitality/Interest/Sponsorship
Hospitality/Interest/Sponsorship Date Received Method of Declaration Abbott Laboratories Limited 23/03/12 Sponsorship Abbott Laboratories Limited 28/05/12 Sponsorship Abbott Laboratories Limited 23/03/12
Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2015 Name: Patrick Pun, MD Title: Asasistant Professor of Medicine Address: DCRI Please complete the applicable rows in the following table. Monetary
Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2016 Name: Shelby D. Reed, PhD Title: Professor Address: PO Box 17969, Durham, NC 27715 Please complete the applicable rows in the following table.
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the
Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD
Simply Wall St provides a completely new visual way to invest in the stock market. To see other infographic reports like this one for Apple check out simplywall.st. Very interesting in all areas. COMPANY
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
State of Licensing 2011 Update
State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-
Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector Publishing Intelligence Limited
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report information for the calendar year 2014 and anticipated
The 2011 EU industrial R&D investment SCOREBOARD
1 The 2011 EU industrial R&D investment SCOREBOARD Joint Research Centre European Commission Héctor Hernández Alex Tuebke Fernando Hervás 1. Background 2 Understanding the dynamics of industrial R&D at
KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018
KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn
PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update
PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease
Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market
Early Valuation. Company Portfolio
Early Valuation Company Portfolio The current strategy Idea PoC Regulatory Clinical Development Basic Science / Experts Operations Marketing / KOL Commercial Health Innovation Technology Transfer 1 I d
4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. Inc. Investor Update February 1, 2019 Key Metrics Assets Under Management Management Fees ($ in billions) ($ in millions) $195 $1,069 $168 $905 $100 $107
Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through
Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through 2015 www.pharmsource.com 1 Presenters Jim Miller President and Founder, PharmSource Saul Richmond, PhD Director of Market Intelligence,
Management to Host Conference Call at 8:30 a.m. ET today
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),
Annual Press Conference Financial year 2017
Annual Press Conference 2018 Financial year 2017 Financial year Hubertus von Baumbach Chairman of the Board of Managing Directors 2017 Highly successful financial year 2017 Major success with human pharmaceuticals
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D
Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D John C. Lechleiter, Ph.D. Chairman, President, and Chief Executive Officer Eli Lilly and Company Washington Biotechnology &
Investor Presentation. November 2018
Investor Presentation November 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn of Assets $81bn Private Equity, Growth Equity
Reference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew.
Reference List Cha, Myoung., and Theresa Lorriman. February 2014. Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew. September 24, 2015. Pharmaceuticals: Value over Volume. Financial
Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive
Job Title Alliance Lead Analytics Specialist Associate Director Associate Director Diagnostics Partnering Associate Director Business Development Associate Director Application Architecture Associate Manager
KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018
KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 ($ in trillions) KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR +21% CAGR Alternative AUM +12% CAGR $190 (1) ($ in billions)
2 nd Quarter Earnings Conference Call
2 nd Quarter Earnings Conference Call KKR & Co. Inc. Investor Update July 26, 2018 Recent Milestones K-1 $ Converted to a Corporation on July 1, 2018 Investor Day held on July 9, 2018 2 Key Metrics Assets
Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Faes Farma SA (FAE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio
HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO HBM at a Glance SIX-listed investment company
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
UBS Pathfinders Trust, Treasury and Growth Stock Series 23
Dear Valued Client: This annual statement contains important information about your investment. The UBS Unit Trust thanks you for making this Pathfinders Trust a part of your financial plan. If you have
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
The 2010 EU industrial R&D investment SCOREBOARD
1 The 2010 EU industrial R&D investment SCOREBOARD Joint Research Centre European Commission Héctor Hernández 2 Contents 1. Background 2. Overall R&D trends 3. Top R&D companies 4. R&D by region 5. R&D
Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%
Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third
Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, Semiconductor historical billings report in 000 US$
Report date: November 10, 2014 Phoenix Semiconductor Philippines Corp (PSPC) to be listed on December 1, 2014 Recommendation: Cautious buy with target price of Php 3.81/share At the final offer price of
NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA
Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on
Born Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.
Board of Directors Håkan Björklund Chairman Born 1956. Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016. Other appointments: Currently serves as Industry Executive at Avista Capital
Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%
Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile
Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
Investor Presentation & Financial Highlights. November 2018
Investor Presentation & Financial Highlights November 2018 Forward Looking Statements Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties.
4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 8, 2018 4Q17 Reflections Fundamentals Are Strong (Dollars in millions, except per unit amounts and unless otherwise stated)
Booz & Company 30 October, Making Ideas Work. The 2012 Global Innovation 1000 Study
30 October, 2012 Making Ideas Work The 2012 Global Innovation 1000 Study Introduction R&D Spending Trends Analysis Front-End Innovation Survey Findings Summary 1 For the past eight years, has examined
North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile North China Pharmaceutical Group Corp. - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bessemer Venture Partners - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing
Confirms 2013 Financial Guidance
Confirms 2013 Financial Guidance PROVIDENCE, R.I.--(BUSINESS WIRE)--Jul. 17, 2013-- Textron Inc. (NYSE: TXT) today reported second quarter 2013 income from continuing operations of $0.40 per share, compared
Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.
Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology
Life Sciences CONFERENCE SERIES. Business Information in a Global Context LIFE SCIENCES IP PORTFOLIO. Business Development Pack
C5 Business Information in a Global Context Life Sciences CONFERENCE SERIES LIFE SCIENCES IP PORTFOLIO Business Development Pack C5 GROUPS LIFE SCIENCES EVENTS Pharmaceuticals, biotechnology, diagnostics,
PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium
PROTECT Project Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium Content of Presentation About IAPO Overview of PROTECT Work Package 4 - New methods for data
KOHLBERG CAPITAL CORPORATION. May 2007
KOHLBERG CAPITAL CORPORATION May 2007 Safe Harbor Statement Private Securities Litigation Reform Act of 1995 Forward Looking Information This presentation may include forward-looking statements. These
Life Sciences. An evolving industry: Today s clusters creating tomorrow s breakthroughs. New Jersey JLL Research
Life Sciences New Jersey 2017 An evolving industry: Today s clusters creating tomorrow s breakthroughs JLL Research 2 New Jersey Over the course of the past 130 years, the pharmaceutical/life sciences
TRENDS IN IP DISPUTES
ASSOCIATION OF CORPORATE COUNSEL LITIGATION COMMITTEE APRIL 25, 2017 TRENDS IN IP DISPUTES DAVID YURKERWICH MANAGING DIRECTOR IP PRACTICE LEADER 1 AGENDA Patent infringement and IPR filing trends Operating
European companies outpace American counterparts in R&D investment growth for the first time in five years
IP/08/1504 Brussels, 15 October 2008 European companies outpace American counterparts in R&D investment growth for the first time in five years R&D investment by EU companies has increased by 8.8% compared
Interim Report. 1 January 31 March Sales reached 3,006 MSEK (3,317) Sales were flat in local currencies. Continued volume growth for snuff
Interim Report 1 January 31 March 2003 Sales reached 3,006 MSEK (3,317) Sales were flat in local currencies Continued volume growth for snuff Operating income declined to 516 MSEK (605) or by 15 percent
Textron Reports First Quarter 2016 Income from Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook
Textron Reports First Quarter 2016 Income Continuing Operations of $0.55 per Share, up 19.6%; Reaffirms 2016 Financial Outlook April 20, 2016 06:30 AM Eastern Daylight Time PROVIDENCE, R.I.--(BUSINESS
Investor Presentation. April 2015
Investor Presentation April 2015 KKR Global Leader in Alternative Asset Management Private Markets Public Markets Capital Markets Q1 2014 Q1 2015 2 Private Equity Energy $62 bn AUM $37 bn AUM $11.5 bn
Life Sciences Outlook
New Jersey 2018 JLL Research Report Life Sciences Outlook Breakthrough discoveries at a breathtaking pace 2 New Jersey The pharmaceutical/life sciences industry has historically been one of New Jersey
Accelerating Pharmaceutical Growth through Open Innovation and Global Collaborations
Sino American Pharmaceutical Professionals Association 美中醫藥開發協會 Accelerating Pharmaceutical Growth through Open Innovation and Global Collaborations August 3-4, 2012 New Jersey, USA PRELIMINARY PROGRAM
Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
WORLD BANK GROUP SENIOR MANAGEMENT TEAM AND VICE PRESIDENTS. FINANCIAL DISCLOSURE FOR CALENDAR YEAR 2011 Summary for Public Disclosure
WORLD BANK GROUP SENIOR MANAGEMENT TEAM AND VICE PRESIDENTS FINANCIAL DISCLOSURE FOR CALENDAR YEAR 2011 Summary for Public Disclosure Name: Position/Title: WBG Organization: Madelyn Antoncic Vice President
Greater Yuma EDC Investors Making News
Greater Yuma EDC Investors Making News May 26, 2016 Issue RCFBH: Mobile Unit Local Seniors Awarded $5K In Scholarships From Alexander Ford Lincoln Johnson Controls Declared A Quarterly Dividend of $0.29
1 st Quarter Earnings Conference Call
1 st Quarter Earnings Conference Call KKR & Co. L.P. Investor Update April 27, 2017 1Q17 Reflections Key Business Themes Performance this quarter was strong as our model enabled us to capture more of everything
Voting Procedure (con t)
2 Voting Procedure 1 ( 5 ) One share shall have one vote. A shareholder may cast his/her vote to either approve, disapprove or abstain from voting. Except for Agenda Item 5 regarding election of directors,
Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio
Scripps Networks Interactive Inc.
January 27, 2015 Scripps Networks Interactive Inc. (SNI-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 01/03/2011 Current Price (01/26/15) $73.49
Aqua Pharmaceuticals, LLC
Aqua Pharmaceuticals, LLC Corporate Presentation June 2011 AQUA PHARMACEUTICALS, LLC 1 Company Overview Specialty dermatology pharmaceutical company currently focusing on acquiring, developing and marketing
GameStop Corp. NASDAQ:GME. HOLD Price Target: $28.74 Key Statistics as of 10/13/2016. Catalysts: Company Description:
GameStop Corp. NASDAQ:GME Analyst: Sector: Christian Henderson Services HOLD Price Target: $28.74 Key Statistics as of 10/13/2016 Catalysts: Short Term ( less than a year) any change in the distribution
Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting Tokyo, Japan March 16, 2010 Astellas Pharma Inc. (TSE: 4503) today notified
Biotech Concerto #6 Investment Process December 2008
Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision
Industrial Investment in Research and Development: Trends and Prospects
MEMO/05/471 Brussels, 9 December 2005 Industrial Investment in Research and Development: Trends and Prospects The 2005 Key Figures for science, technology and innovation released last July showed EU R&D
Activision Blizzard, Inc. ATVI NASDAQ Neutral-2
COMPANY UPDATE / ESTIMATE CHANGE / RATING CHANGE Key Metrics ATVI - NASDAQ (as of 11/7/17) $60.96 Price Target N/A 52-Week Range $35.12 - $67.03 Shares Outstanding (mil) (basic) 755 Market Cap. ($mil)
KKR & Co. L.P. Morgan Stanley Financials Conference June 2014
KKR & Co. L.P. Morgan Stanley Financials Conference June 2014 DISCLAIMER: This presentation will also contain forward-looking statements, which do not guarantee future events or performance. Please refer
Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018
Q4 & FY18 PERFORMANCE HIGHLIGHTS JUNE 2018 Index Result Highlights 3 Operational Metrics 7 Financial Summary 10 New product offerings 14 Awards & Accolades 17 Annexure 19 Safe Harbour Statement The documents
For personal use only. EBOS Group Limited. 94 th Annual Meeting. 19 October 2016
EBOS Group Limited 94 th Annual Meeting 19 October 2016 Important Information The information in this presentation was prepared by EBOS Group Ltd with due care and attention. However, the information is
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018
Capcom Co., Ltd. (Tokyo Stock Exchange, First Section, 9697) Financial Highlights for the Fiscal Year ended March 31, 2018 0 0 Forward-looking Statements Strategies, plans, outlooks and other statements
Speakers Bio: Jenny Tian Managing Director
Speakers Bio: Jenny Tian Managing Director Jenny has been in the investment management industry for most of her career which started in 1998. Prior to her current roles in the Springs Capital top management
MASTERCARD INC FORM 8-K. (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08
MASTERCARD INC FORM 8-K (Current report filing) Filed 09/11/08 for the Period Ending 09/09/08 Address 2000 PURCHASE STREET PURCHASE, NY 10577 Telephone 9142492000 CIK 0001141391 Symbol MA SIC Code 7389
Pharmaceutical Co., Ltd. MEDICINE CNS/ENDOCRINOLOGY DEVELOPMENT LICENSING COMPANY PROFILE
WHANIN Pharmaceutical Co., Ltd. MEDICINE CNS/ENDOCRINOLOGY DEVELOPMENT LICENSING COMPANY PROFILE Board of Directors Chairman Vice Chairman President & CEO Vice President, Marketing Director (non-standing)
NVESTOR. 1,400+ Attendees. 2,700+ Partnering Meetings. 768 Companies. 700 Registered Investors. 158 Company Presentations
February 11-12, 2019 New York Marriott Marquis Now in its 21 st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and
Overview of Venture Equity
Overview of Venture Equity SVB Analytics Report 2017 Written by SVB Analytics: Steve Liu Managing Director sliu@svb.com Sean Lawson Senior Manager slawson2@svb.com Steven Pipp Senior Associate spipp@svb.com
ANNUAL GENERAL MEETING 27 JULY Copyright Tate & Lyle PLC 2017
ANNUAL GENERAL MEETING 27 JULY 2017 Copyright Tate & Lyle PLC 2017 DR GERRY MURPHY Chairman 2 JAVED AHMED Chief Executive 3 Year of strong progress and delivery Commercial Operational Financial Speciality
Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business
Corporate Profile January 2011 OTCBB:LBMH
Corporate Profile January 2011 Business Description Liberator Medical Holdings, Inc. s ( Liberator Medical or the Company ) wholly owned subsidiary, Liberator Medical Supply, Inc. is a national direct-to-consumer
4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 11, 2016 Gross Returns $1B+ Carry Paying Funds Q4 and 2015 Performance Market Indices Private Equity Real Assets Alternative
Holiday Trading Hours
Us stocks 24.12.15 25.12.15 31.12.15 01.01.2016 Alibaba close at 18:00 GMT Closed close at 18:00 GMT Closed Amazon close at 18:00 GMT Closed close at 18:00 GMT Closed AMEX close at 18:00 GMT Closed close
2009 Half Year Results Summary
Rig Activity - 2 - 2009 Half Year Results Summary 2009 m 2008 m Change % Revenue 219.8 201.2 +9% EBITDA 30.7 32.1-4% Profit from operations 23.0 24.0-4% Finance income (expense) 3.3 (2.9) Profit before
MOVING WATER. MOVING FUEL. MOVING FORWARD.
MOVING WATER. MOVING FUEL. MOVING FORWARD. ANNUALREPORT2013 SEPTEMBER 2013 COMPLETED RELOCATION TO OUR NEW WORLD HEADQUARTERS Franklin Electric Co., Inc. 9255 Coverdale Road Fort Wayne, Indiana 46809 telephone:
BRUKER CORP FORM 8-K. (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12
BRUKER CORP FORM 8-K (Current report filing) Filed 06/07/12 for the Period Ending 06/04/12 Address 40 MANNING RD BILLERICA, MA, 01821 Telephone 978663-3660 CIK 0001109354 Symbol BRKR SIC Code 3826 - Laboratory
Generics Series: Authorized Generics Analysis Stemming the Generics Tide
Generics Series: Authorized Generics Analysis Stemming the Generics Tide Report summary An overview of the authorized generics landscape, including drivers and resistors for both branded and generics players
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within
SAA s Structured Peer Group Analysis. STRATEGIC ASSET ALLIANCE, INC. Document not to be reproduced without the explicit consent of SAA.
SAA s Structured Peer Group Analysis Bonds Rated BBB*/Surplus This chart indicates your company s fixed income exposure to BBB rated bonds relative to your peers. Companies tend to increase BBB allocations
4 th Quarter Earnings Conference Call
4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 9, 2017 Healthy Level of New Capital Raised Year-Over-Year Capital Inflows Driving Asset Growth ($ in billions) $92 +11% $101